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Background: The current consensus definition of severe sepsis and septic
shock includes a heterogeneous profile of patients under the same
definition. Although the prognostic value of hyperlactatemia in sepsis is
well established, hyperlactatemia can be found both in severe sepsis and
septic shock patients. We sought to compare features and outcomes of
septic patients stratified by two factors: the presence of hyperlactemia
and persistent hypotension.
Materials and methods: This was a secondary analysis of a multicenter
observational study from 10 private hospitals in Brazil (Rede Amil-SP)
aiming to evaluate the impact of a multifaceted program to implement the
Surviving Sepsis Campaign bundles. We retrieved 1,948 septic patients
with an initial lactate level collected within the first 6 hours of diagnosis.
Based on previous literature, we stratified them into four groups according
to the presence of hypoperfusion (lactate >4 mmol/l) and/or persistent
hypotension despite adequate fluids: 1, severe sepsis (without both criteria);
2, cryptic shock (hypoperfusion without persistent hypotension) [1];
3, vasoplegic shock (persistent hypotension without hypoperfusion); and 4,
dysoxic shock (with both criteria) [2].
Results: Severe sepsis was found in 1,018 (52%), cryptic shock in 162
(8%), vasoplegic shock in 549 (28%) and dysoxic shock in 219 (12%)
patients. Mean age was 60 years, 47% were male and the majority was
admitted form the emergency department (47%). The lung was the
principal source of infection, followed by the urinary tract and abdominal.
Overall, the four groups presented significant differences in APACHE II
and SOFA scores (P < 0.001 for both), dysoxic shock being the most
severe group. In post-hoc analysis, patients in the severe sepsis group
presented similar SOFA score to patients in the cryptic shock group (P =
0.20). Overall, 28-day crude survival was different between groups (P <
0.001), being higher for the severe sepsis group (69%, P < 0.001 vs.
other), similar between cryptic and vasoplegic shock (53%, P = 0.39) and
lower for dysoxic shock (38%, P < 0.001 vs. other). In an adjusted analysis
considering age, APACHE II and SOFA, the 28-day survival remained
different between groups (P < 0.001) and the hazard ratio for the dysoxic
shock group was the highest: HR 2.99 (95% CI 2.21 to 4.05).
Conclusions: Current definitions for severe sepsis and septic shock
include four different phenotypes, which should be considered for
epidemiology purposes, customizing treatment goals and inclusion
criteria for future studies. Although previous studies showed similar
outcomes between cryptic shock and overt septic shock (vasoplegic and
dysoxic profile), we demonstrated that cryptic shock is similar only to
vasoplegic shock.
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Background: Antithrombin III (AT III) has been known to contribute to
anti-inflammatory response as well as its anticoagulation. Our previous
study showed AT III deficiency happened in the early stage of sepsis with
no relation to disseminated intravascular coagulation (DIC) status.
Whether AT III concentrate is a beneficial therapy or not for septic
patients is still a controversial issue. Our hypothesis is that AT III
concentrate may have efficacy as an anti-inflammatory for sepsis.
Materials and methods: From January 2009 to June 2013, adult septic
patients with nonovert DIC whom were given AT III concentrate in our
medico-surgical ICU were included in this study. DIC scoring was used
with the definition of the International Society on Thrombosis and
Haemostasis (ISTH). AT III concentrate was administered 30 to 60 U/kg
intravenously every 24 hours for 3 days in the patients. Between before
and after the AT III concentrate therapy, WBC (/mm3), CRP (mg/dl),
platelet (×104/μl), PT (seconds), fibrinogen (mg/dl), FDP (μg/ml), SOFA
score and DIC score by ISTH were compared. Values are expressed as
mean ± SD. Data were analyzed by Wilcoxon signed-rank test. P < 0.05
was considered significant.
Results: There were 157 patients (100 men, 57 women; age range 19 to
96 years (mean 70.0 ± 16.0)), and the 28-day mortality rate was 25.5%
and APACHE II score was 17.2 ± 8.3. WBC, CRP, PT, and SOFA score were
significantly improved after AT III concentrate therapy (13,411 ± 8,794 vs.
11,798 ± 6,562, P = 0.0007, 17.1 ± 11.5 vs. 13.9 ± 7.0, P = 0.0001, 16.5 ±
10.9 vs. 15.2 ± 5.3, P = 0.002, and 8.6 ± 3.6 vs. 7.7 ± 4.5, P = 0.005,
respectively), although platelet was significantly decreased (15.8 ± 11.3 vs.
13.7 ± 11.3, P < 0.00013). There were no significant differences in
fibrinogen, FDP and DIC score (464.7 ± 235 vs. 437.6 ± 185.4, P = 0.10,
25.1 ± 36.9 vs. 25.6 ± 36.2, P = 0.85, 2.0 ± 1.5 versus 2.3 ± 1.7, P = 0.06,
respectively). One week after the therapy, SOFA score was significantly
improved, while the DIC score did not change compared with before the
therapy (6.1 ± 4.7, P < 0.0001 and 2.3 ± 1.7, P = 0.98).
Conclusions: In the patients with septic nonovert DIC, WBC, CRP and
SOFA score were immediately improved after the AT III concentrate
therapy, while fibrinogen, FDP and DIC score did not change. AT III
concentrate may also contribute to anti-inflammatory without DIC
status.
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Background: Intravenous immunoglobulin (IVIG) administration has been
approved to use for severe sepsis with antibiotics by the Ministry of
Health, Labour and Welfare since 1980 in Japan. IVIGs are commonly
used for severe sepsis and septic shock in Japan, while the international
guidelines for management of severe sepsis and septic shock in 2012
suggest not using IVIG in adult patients. Our hypothesis is that IVIG
administration has an efficacy for severe sepsis and septic shock.
Materials and methods: This retrospective observational study included all
adult patients in our ICU who were administered IVIG for severe sepsis and
septic shock from January 2011 to June 2013. IVIG was used at 5,000 mg/day
every 24 hours for 3 days. We compared body temperature (°C), WBC (/mm3),
CRP (mg/dl), procalcitonin (ng/ml) and serum immunoglobulin G (IgG)
(mg/dl; normal >870) between before and after IVIG treatment. Values are
expressed as the median. The Wilcoxon signed-rank test was used for the
statistical analysis. P < 0.05 was considered significant.
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Results: One hundred and fifty-one patients (85 men, 66 women; age
range 23 to 96 (median 67.8)) were included in this study. The 28-day
mortality after IVIG treatment was 13.9%. The SOFA score before IVIG
treatment was 5.0. Values of WBC, CRP and procalcitonin were significantly
decreased after IVIG treatment (10,905 vs. 9,805, P < 0.0001, 12.3 vs. 7.7,
P < 0.0001, 2.4 vs. 1.7, P = 0.0003, respectively). Body temperature did not
significantly change (37.4 vs. 37.2, P = 0.07). Serum IgG was significantly
increased after the treatment (1,046 vs. 1,563, P = 0.003).
Conclusions: The present study has some limitations because of being a
retrospective observational study. However, the mortality was quite low in
the group of patients included in this study. Moreover, after IVIG treatment
values of WBC, CRP and procalcitonin were improved. The median value of
serum IgG before treatment was within the normal range, but after
treatment was also significantly improved. There is a possibility that severe
septic patients require additional IgG regardless of its normal concentrations
in their blood.
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Background: In our previous study, we reported that polymyxin B-direct
hemoperfusion (PMX-DHP) (Toraymyxin®; Toray Medical Co., Tokyo, Japan)
therapy could contribute to oxygen delivery due to improved hemodynamic
status, while decreasing inotropic agents in septic patients immediately after
that treatment. The randomized controlled studies are ongoing in other
countries, because its efficacy and indication are still controversial issues.
The purpose of this study is to evaluate whether PMX-DHP therapy sustains
to improve hemodynamic status after the treatment.
Materials and methods: All adult patients treated with PMX-DHP and
receiving a pulmonary arterial catheter (PAC) in our ICU from July 1994 to
June 2010 were included in this retrospective observational study.
Patients’ clinical, microbiological and PAC data were collected from
medical archives. PAC variables were compared between immediately
before and after 24 hours of PMX-DHP therapy. Values were expressed as
mean ± SD. Data were analyzed by Wilcoxon signed-rank test. P < 0.05
was considered statistically significant.
Results: There were 63 patients (36 men, 27 women; age mean 63.4 ±
14.8) studied. The mortality rate was 30.2% 28 days after PMX-DHP.
APACHE II score and SOFA score on the day of PMX-DHP therapy were
20.2 ± 14.8 and 7.3 ± 3.8, respectively. Mean arterial pressure (MAP)
(mmHg) was significantly increased after PMX-DHP therapy (77.5 ± 22.5 vs.
87.2 ± 15.9, P = 0.02). The inotropic score decreased 24 hours after PMX-
DHP, but did not reach statistical change (10.0 ± 16.1 vs. 6.3 ± 11.6, P =
0.08). The cardiac index (CI) (l/minute/m2), systemic venous resistance
index (SVRI) (dyn·second·m2/cm5), mixed venous oxygen saturation (SvO2)
(%), oxygen delivery and consumption (DO2 and VO2) (ml/minute) and P/F
ratio were not statistically different before and after PMX-DHP therapy.
Conclusions: Only the increasing of MAP was sustained after 24 hours of
PMX-DHP therapy, while the inotropic agents were decreased. Although
the CI, DO2, VO2, and P/F ratio were improved immediately after PMX-
DHP therapy in our previous study, these were not significantly changed
between before and after 24 hours. PMX-DHP could improve MAP with
decreasing inotropic agents, while alterations of other PAC variables were
not sustained in 24 hours of PMX-DHP.
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Background: Information about the prevalence of fungal diseases in
critically ill AIDS patients is sparse. Our goal is to describe the prevalence
of fungal diseases in this population, when they are admitted to the ICU.
Materials and methods: Prospective, observational study. Blood and
urine samples were collected from 65 AIDS patients at a specialized ICU
in infectious diseases, from August 2011 to June 2013. When indicated by
clinical suspicion, samples of respiratory, bone marrow and/or tissue were
collected. Cultures, cytopathology and serologic tests were performed to
evaluate fungal colonization or infection. Clinical data were collected
from medical records. Values are expressed as the median and
percentage.
Results: Table 1 presents general characteristics of the HIV/AIDS patients.
Patients with fungal disease did not differ from patients without fungal
infection: age 35 versus 38 years (P = 0.43), male gender 76% versus 70%
(P = 0.29); nadir CD4 cell count 27 versus 57 cell/mm3 (P = 0.15). Most
patients were exposed to HAART previously, while there were 47% naïve
patients in the fungal group versus 31% in the no fungal group. The ICU
mortality of patients without fungal disease was 31% versus 64.7% with
fungal disease (P = 0.02); hospital mortality was not different between
groups (52% vs. 64.7%, P = 0.4). Figure 1 presents 17 diagnoses of
disseminated fungal diseases (prevalence 26%). All histoplasmosis
diagnoses were made from marrow bone culture (11%). Disseminated
cryptococcosis was diagnosed from serum serologic latex, direct
examination and positive culture in LCR. Three patients (4.6%) were
diagnosed with candidiasis in blood cultures. Pnemunocystosis was
diagnosed from immunofluorescence and Grogot positive in sputum. One
patient had disseminated esporotricosis with positive cultures in LCR,
blood, tissue, urine and sputum. The only case of aspergilosis is a
previous tuberculosis-treated patient that developed a disseminated
disease (galactomanana-positive) from a fungal ball.
Conclusions: One in four HIV/AIDS critically ill patients presents with
fungal disease when they are admitted to the ICU. Surveillance of fungal
pathogens shall be necessary in the first screening of medical HIV/AIDS
patients in the ICU.






Age (years) 38 (31 to 43) 35 (33 to 46) 0.43
Gender (male) 34 (71%) 13 (76%) 0.29
CD4+ lymphocyte
count (cell/mm3)
69 (32 to 204) 28 (14 to 115) 0.15
Nadir CD4+ (cell/mm3) 57 (27 to 153) 27 (14 to 122) 0.40
Time since HIV diagnosis
(months)
31 (1 to 123) 13 (1 to 77) 0.53
HAART näive 15 (31%) 8 (47%) 0.56
Mortality 15 (31%) 11 (64.7%) 0.02
Figure 1(abstract P41) Fungal diseases.
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